Design and Clinical Verification of Surface-Enhanced Raman Spectroscopy Diagnostic Technology for Individual Cancer Risk Prediction.
暂无分享,去创建一个
Jing Wang | Matt Trau | Robert A Gardiner | K. M. Koo | Kevin M Koo | H. Samaratunga | J. Yaxley | M. Lavin | R. Gardiner | P. Mainwaring | M. Trau | M. Roberts | Martin F Lavin | G. Coughlin | Yuling Wang | Hema Samaratunga | Patrick E Teloken | Jing Wang | Yuling Wang | Matthew J Roberts | John W Yaxley | Geoffrey D Coughlin | Renée S Richards | Aine Farrell | Paul N Mainwaring | P. Teloken | A. Farrell
[1] R. Álvarez-Puebla,et al. Conformational SERS Classification of K-Ras Point Mutations for Cancer Diagnostics. , 2017, Angewandte Chemie.
[2] Javed Siddiqui,et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. , 2016, European urology.
[3] John T. Wei,et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. , 2013, Urologic oncology.
[4] Jordan J. Feld,et al. Clinical Validation of Quantum Dot Barcode Diagnostic Technology. , 2016, ACS nano.
[5] L. Marks,et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. , 2006, Clinical chemistry.
[6] Cheng Zong,et al. Label-free surface-enhanced Raman spectroscopy detection of DNA with single-base sensitivity. , 2015, Journal of the American Chemical Society.
[7] J. Gohagan,et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow‐up of 15 years , 2017, Cancer.
[8] C. Mirkin,et al. Nanoparticles with Raman spectroscopic fingerprints for DNA and RNA detection. , 2002, Science.
[9] B. Conley,et al. Bridging the Gap: Moving Predictive and Prognostic Assays from Research to Clinical Use , 2012, Clinical Cancer Research.
[10] R. Álvarez-Puebla,et al. Ultrasensitive Direct Quantification of Nucleobase Modifications in DNA by Surface-Enhanced Raman Scattering: The Case of Cytosine. , 2015, Angewandte Chemie.
[11] Michael W. Kattan,et al. Prostate cancer: Personalized risk — stratified screening or abandoning it altogether? , 2016, Nature Reviews Clinical Oncology.
[12] P. Prorok,et al. Prostate Cancer Screening - A Perspective on the Current State of the Evidence. , 2017, The New England journal of medicine.
[13] S. Nie,et al. Quantum-dot-tagged microbeads for multiplexed optical coding of biomolecules , 2001, Nature Biotechnology.
[14] Z. Hall. Cancer , 1906, The Hospital.
[15] G. Cancel-Tassin,et al. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer , 2013, The Prostate.
[16] R. Álvarez-Puebla,et al. Silver colloids as plasmonic substrates for direct label-free surface-enhanced Raman scattering analysis of DNA. , 2016, The Analyst.
[17] D. McLean,et al. Automated Autofluorescence Background Subtraction Algorithm for Biomedical Raman Spectroscopy , 2007, Applied Spectroscopy.
[18] Matt Trau,et al. A nanoplasmonic label-free surface-enhanced Raman scattering strategy for non-invasive cancer genetic subtyping in patient samples. , 2017, Nanoscale.
[19] T. D. de Reijke,et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. , 2014, European urology.
[20] Matt Trau,et al. Rapid and Sensitive Fusion Gene Detection in Prostate Cancer Urinary Specimens by Label-Free Surface-enhanced Raman Scattering. , 2016, Journal of biomedical nanotechnology.
[21] R. Álvarez-Puebla,et al. Fast Optical Chemical and Structural Classification of RNA. , 2016, ACS nano.
[22] Kan Wang,et al. Breath Analysis Based on Surface-Enhanced Raman Scattering Sensors Distinguishes Early and Advanced Gastric Cancer Patients from Healthy Persons. , 2016, ACS nano.
[23] R. Álvarez-Puebla,et al. Direct surface-enhanced Raman scattering analysis of DNA duplexes. , 2015, Angewandte Chemie.
[24] W. Bablok,et al. A New Biometrical Procedure for Testing the Equality of Measurements from Two Different Analytical Methods. Application of linear regression procedures for method comparison studies in Clinical Chemistry, Part I , 1983, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.
[25] Leonard S. Marks,et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. , 2006, Clinical chemistry.
[26] Jennifer A. Dougan,et al. Positively charged silver nanoparticles and their effect on surface-enhanced Raman scattering of dye-labelled oligonucleotides. , 2012, Chemical communications.
[27] W. Chan,et al. Patients, Here Comes More Nanotechnology. , 2016, ACS nano.
[28] R. Álvarez-Puebla,et al. The Structure of Short and Genomic DNA at the Interparticle Junctions of Cationic Nanoparticles , 2017 .
[29] Matt Trau,et al. Toward Precision Medicine: A Cancer Molecular Subtyping Nano-Strategy for RNA Biomarkers in Tumor and Urine. , 2016, Small.
[30] Douglas K Owens,et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.
[31] Yuling Wang,et al. Enabling miniaturised personalised diagnostics: from lab-on-a-chip to lab-in-a-drop. , 2017, Lab on a chip.
[32] Nallasivam Palanisamy,et al. Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA , 2011, Science Translational Medicine.